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Introduction 
Chronic lymphocytic leukemia (CLL) patients present a
progressive immunodeficiency due to the ability of CLL cells
to manipulate their microenvironment, escaping immunosur-
veillance and inducing immunosuppression. CLL cells evade
immune detection through different mechanisms involving
secretion of immunosuppressive cytokines and formation of
the protective niches needed to change the function of
immune effector cells and to escape drug-induced apoptosis.1
In addition, alteration of different signaling molecules
involved in actin polymerization influences the communica-
tion between CLL cells and effector cells.2 CLL cells are
accompanied by an expanded population of regulatory and
exhausted T cells, and surrounded by a macrophage popula-
tion with M2 properties and dysregulated expression of mol-
ecules involved in antigen-presentation and immune
response.3
Nurse-like cells (NLCs) are round or fibroblast-shaped
adherent cells differentiated from peripheral blood-derived
monocytes in vitro. NLCs can also be detected in lymph nodes
(LN) of CLL patients.4-6 NLCs share several features with
tumor-associated macrophages: secretion of IL10, IL8, but not
IL12; high surface expression of CD11b, HLA-DR, CD163,
CD206; and expression of indoleamine 2,3-dioxygenase
(IDO).3,5,7 Furthermore, NLCs also show deregulated expres-
sion of genes involved in immunocompetence.8 NLCs protect
leukemic cells from undergoing spontaneous or drug-induced
apoptosis in a contact-dependent manner.9 
Lenalidomide is an immunomodulatory agent (IMID) clini-
cally active in patients with CLL.10-12 The mechanism of action
of lenalidomide includes ‘re-educating’ immune cells such as
T cells, monocytes and NK cells, increasing anti-tumor immu-
nity in CLL.13 By in vitro studies and in the TCL1 mouse model
for CLL, lenalidomide was shown to reverse defects in adhe-
sion and motility functions, as well as in immunological
synapse formation between CLL and T cells, by modulating
several cytoskeletal molecules.14-16 Recently, lenalidomide was
also shown to interfere with the mutualistic interaction
between CLL and NLCs.17
Together these findings prompted us to investigate the
functional effects of lenalidomide on NLCs in CLL. We found
that lenalidomide modifies CLL-circulating monocytes,
inducing firm adhesion to endothelium and loss of migration
through modulation of small GTPases. Lenalidomide induces
a pro-inflammatory profile in NLCs improving their phago-
cytic activity and ability to activate T-cell proliferation.
Overall, our study provides new insights into the mode of
action of lenalidomide that targets microenvironmental ele-
ments interfering with the supporting and protective milieu
generated by CLL cells into tissues.  
Methods 
A detailed description of the protocols used is available in the Online
Supplementary Appendix.
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Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The spe-
cific mechanism of action is still undefined, but includes modulation of the microenvironment. In chronic lympho-
cytic leukemia patients, nurse-like cells differentiate from CD14+ mononuclear cells and protect chronic lympho-
cytic leukemia cells from apoptosis. Nurse-like cells resemble M2 macrophages with potent immunosuppressive
functions. Here, we examined the effect of lenalidomide on the monocyte/macrophage population in chronic lym-
phocytic leukemia patients. We found that lenalidomide induces high actin polymerization on CD14+ monocytes
through activation of small GTPases, RhoA, Rac1 and Rap1 that correlated with increased adhesion and impaired
monocyte migration in response to CCL2, CCL3 and CXCL12. We observed that lenalidomide increases the num-
ber of nurse-like cells that lost the ability to nurture chronic lymphocytic leukemia cells, acquired properties of
phagocytosis and promoted T-cell proliferation. Gene expression signature, induced by lenalidomide in nurse-like
cells, indicated a reduction of pivotal pro-survival signals for chronic lymphocytic leukemia, such as CCL2, IGF1,
CXCL12, HGF1, and supported a modulation towards M1 phenotype with high IL2 and low IL10, IL8 and CD163.
Our data provide new insights into the mechanism of action of lenalidomide that mediates a pro-inflammatory
switch of nurse-like cells affecting the protective microenvironment generated by chronic lymphocytic leukemia
into tissues. 
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ABSTRACT
Patients and samples
Written informed consent was obtained in accordance with the
Declaration of Helsinki with a protocol approved by the local
Institutional Review Board. CD14+ monocytes were obtained by
immunomagnetic selection. To generate NLCs, PBMCs from CLL
patients were cultured (107/mL) as previously described.18
Lenalidomide was used at the clinically relevant doses of 0.5 mM,
1 mM and 10 mM as in previous studies.2,16,17,19
Actin polymerization
Actin polymerization was inspected in monocytes and in NLCs
from CLL patients with F-actin Visualization Biochem Kit
(Cytoskeleton, Denver, CO, USA).
Adhesion assays
CD14+ monocytes from 10 CLL patients were added onto the
confluent HUVEC (Life Technologies) layer and allowed to adhere
for 2 h at 37°C. After incubation, monocytes were treated with
lenalidomide 0.5 mM for 20 min or vehicle. In some experiments,
adherent monocytes (n=6) were treated with Rac1 inhibitor
(50mM) or Rap1 inhibitor (10 mM) for 30 min. Then, monocytes
firmly adherent to HUVEC were counted by staining with CD14
APC antibody (Miltenyi Biotec), as previously described.20
Furthermore, adhesion of CLL cells on NLCs was also evaluated.
We generated NLCs from PBMCs (n=7), treated or not with
lenalidomide 0.5 mM or 1 mM or vehicle. Firmly adherent CLL cells
were collected and counted by CD19 staining. 
Chemotaxis assays
Migration assays on CLL monocytes (n=5) treated or not with
0.5 mM lenalidomide were performed using 5-mm pore PET inserts
(Millipore, Billerica, MA, USA), as previously described.21 
Gene expression analysis
Gene expression profiling (GEP) was performed by hybridizing
RNA of NLCs treated with lenalidomide 0.5 mM or vehicle (con-
trol) for ten days (n=4) on 4X44K Whole Human Genome
Microarray (Agilent Technologies, Palo Alto, CA, USA) as previ-
ously described.22 Gene transcripts were also amplified using
LightCycler 480 SYBR Green I Master Mix (Roche). Primers are
listed in Online Supplementary Table S1. 
Immunoblotting 
CD14+ monocytes were cultured in the presence of lenalido-
mide or vehicle for 4 h at 37°C. Proteins (100 mg/lane) were elec-
trophoresed and membranes were immunoblotted with primary
antibodies listed in Online Supplementary Table S2.
Flow cytometry
Nurse-like cells were stained with the following antibodies and
corresponding isotype controls: APC-conjugated CD14 (Miltenyi
Biotec), CD163, CD11b (BD Biosciences Pharmingen, San Jose,
CA, USA) and PE-conjugated CD11b CBRM 1/5 (eBioscience). 
Phagocytosis assays
Phagocytosis was inspected using CytoSelectTM 96-Well
Phagocytosis assay (Cell Biolabs, San Diego, CA, USA). In a sepa-
rate set of experiments, NLCs were generated on coverslips with
lenalidomide or vehicle and FITC-dextran particle engulfment was
quantified as previously described.23 
Cell activation and proliferation
Nurse-like cell activation was monitored using MTT assay
(Trevigen, Gaithersburg, MD, USA). NLC proliferation was evalu-
ated using CFSE dilution assay, Ki-67 staining and cell cycle analy-
sis. Allogeneic mixed lineage reactions were performed to meas-
ure T-cell proliferation.
Cytokine secretion assay
To determine secretion of IL-2, NLCs were analyzed using the
Cytokine Secretion Assay (CSA) for IL-2 (CSA Detection Kit;
Miltenyi Biotec).
Statistical analyses
Data were analyzed using SPSS v.20.0 (SPSS, Chicago, IL, USA).
P values were calculated by Student t-test (*P<0.05, **P<0.01). 
Results
Lenalidomide induces actin polymerization in 
monocytes derived from CLL patients
Immunomodulatory drugs (IMiDs) such as lenalidomide
were shown to activate Rho family GTPases and induce
cytoskeleton reorganization.24 To evaluate whether
lenalidomide could affect actin cytoskeleton in monocytes
from CLL patients, we treated purified CD14+ monocytes
(n=9) with lenalidomide for 20 min at doses ranging from
0.5 mM to 10 mM and measured the F-actin content.
Lenalidomide stimulated actin polymerization at the clin-
ically relevant doses of 0.5 mM and 1 mM (Figure 1A). In
particular, F-actin formation increased to 174% (±27%),
300% (±62%), and 350% (±131%) upon stimulation with
0.5 mM, 1 mM and 10 mM lenalidomide, respectively, com-
pared to unstimulated control (100%) (n=9; P<0.05 in all
cases) (Figure 1B). 
In addition, we asked ourselves whether lenalidomide
induced actin polymerization by activating specific
GTPases. To investigate this, in a separate set of experi-
ments, lenalidomide-induced actin polymerization in CLL
monocytes from 8 patients was measured after blocking
ROCK1, Rap1 or Rac1 kinases by using specific inhibitors.
These agents invariably reduced lenalidomide-induced
actin polymerization in CLL monocytes (Figure 1C).
Specifically, addition of Y27632 (ROCK1 inhibitor), GGTI-
268 (Rap1 inhibitor), and Rac1-specific inhibitor reduced
the effect of lenalidomide from 288% (±46%) to 162%
(±31%), 190% (±48%) and 177% (±7%), respectively
(P<0.05 in all cases) (Figure 1D). However, the specific
inhibition of each GTPase did not completely neutralize
the stimulation of F-actin formation mediated by lenalido-
mide, suggesting that other molecular mediators are
involved in actin polymerization (Figure 1D). Thus,
lenalidomide promotes the activation of Rho-family small
GTPases, RhoA and Rac1 and Ras-family small GTPase
Rap1, stimulating actin polymerization in circulating
monocytes from CLL patients.
Lenalidomide improves adhesion and impairs migration
of CLL monocytes
The actin cytoskeleton supports a multitude of essential
functions in adherent and migrating cells from participat-
ing in the formation of protrusions to the generation of
tensile forces and cell motility. Thus, we speculated that
the cytoskeleton reorganization, induced by lenalidomide
treatment, might modify adhesive and migratory proper-
ties of CLL monocytes. First, we inspected the adhesive
potential of monocytes by culturing CD14+ cells on
HUVEC monolayers. Lenalidomide treatment strongly
stimulated monocyte adhesion to the HUVEC layer,
increasing to 238% (±37%) the mean relative adhesion
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compared to the untreated control (100%) (n=10; P<0.05)
(Figure 2A and B). Accordingly, treatment with lenalido-
mide improved the amount of ILK (integrin linked kinase)
and phosphorylated Akt in CD14+ CLL monocytes (Figure
2C). In agreement with a role for small GTPases, adhesion
induced by lenalidomide (204%±46%) was significantly
reduced in the presence of Rac1 (123%±34%) or Rap1
(67%±7%) inhibitors (n=6; P<0.05 in all cases) (Figure
2D). These data demonstrate that lenalidomide promotes
monocyte adhesion by Rap1 and Rac1 signaling path-
ways. IMiDs were shown to increase migration of normal
monocytes and to repair motility dysfunction of T cells
from CLL patients.16,24 Conversely, IMiDs impaired migra-
tion capability of CLL cells and endothelial cells.17,25 To
Lenalidomide effect on NLCs
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Figure 1. Lenalidomide induces actin polymerization
in circulating monocytes from CLL patients through-
out Rho and Ras family GTP-binding proteins. (A and
B) Monocytes purified from peripheral blood mononu-
clear cells (PBMC) of 9 CLL patients were allowed to
adhere and then treated with lenalidomide at the
indicated concentrations or vehicle (DMSO) for 20
min. F-actin content was then inspected by rho-
damine-phalloidin staining. (A) Two representative
samples. (B) Quantification of cell staining, as mean
value obtained from 5 different fields at 400X magni-
fication normalized on control (100%, DMSO-treated
monocytes). Lenalidomide induces actin polymeriza-
tion in monocytes from CLL patients.  Data represent
8 independent experiments. Columns and error bars
represent mean±SEM (Student t-test, *P<0.05). 
(C and D) Monocytes from 8 CLL patients were treat-
ed with ROCK, Rap1 and Rac1 inhibitors for 30 min
before stimulation with lenalidomide 1 mM or DMSO
for an additional 20 min and measurement of the 
F-actin content.  Quantification of staining, as mean
fluorescence intensity value obtained from individual
cells from 5 different fields at 400X magnification, is
normalized on control (100%, inhibitors-untreated
DMSO-treated monocytes). Lenalidomide mediates
actin polymerization through the activation of RhoA,
Rac1 and Rap1 GTPases. (C) One representative
case. (D) Histograms represent mean±SEM of 7 inde-
pendent experiments (Student t-test, *P<0.05).  
Figure 2. Lenalidomide promotes CLL monocytes
adhesion to endothelium. (A) CD14+ monocytes
from CLL patients (n=10) were allowed to adhere to
HUVEC layer for 2 h and then treated with lenalido-
mide 0.5 mM or vehicle (DMSO). Histograms repre-
sent the mean relative adhesion of lenalidomide-
treated monocytes compared to the untreated con-
trol. Data represent 8 independent experiments.
Columns and error bars represent mean±SEM
(Student t-test, *P<0.05). (B) Representative May-
Grunwald Giemsa staining shows CLL monocytes
adhesion to HUVEC in presence or absence of
lenalidomide 0.5 mM. (C) Western blot analysis of
CLL CD14+ monocytes was performed with ILK,
anti-phospho Akt, total Akt and β-actin antibodies
after 4 h of treatment with lenalidomide. The
immunoblots show ILK and Akt activation in one
representative case. Densitometric quantification
of bands normalized to the untreated control is
shown below the immunoblots. (D) Monocytes from
6 CLL patients were treated with Rac1 inhibitor or
Rap1 inhibitor or both for 30 min before stimula-
tion with lenalidomide 0.5 mM for an additional 20
min. Histograms represent the mean relative adhe-
sion to HUVEC. (Student t-test, *P<0.05).
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determine the effects exerted by lenalidomide on CLL
monocytes, we performed chemotaxis assays on mono-
cytes (n=5) treated with 0.5 mM lenalidomide or vehicle
using 10 ng/mL CCL2, 10 ng/mL CCL3, and 200 ng/mL
CXCL12 as chemoattractants. Stimulation of monocyte
migration mediated by CCL2 (217%±37%), CCL3
(181%±10%), and CXCL12 (166%±17%) was reduced by
exposure with lenalidomide to 163% (±26%), 123%
(±12%) and 143% (±22%), respectively (n=5; P<0.05 in all
cases) (Figure 3A). We explored the mechanisms involved
in lenalidomide-induced migration impairment. We
excluded the possibility that lenalidomide affects viability
(data not shown) or modified the expression levels of
chemokine receptors during the migration assay (n=6)
(Figure 3B). Lenalidomide was reported to modulate the
expression of the Rho GTPase RhoH, and the actin bind-
ing protein CORO1B in T lymphocytes and CLL cells.17,26,27 
We monitored the expression levels of RhoH and
CORO1B mRNA in CLL monocytes (n=6) treated for 4 h
with lenalidomide 0.5 mM. Lenalidomide increased the
expression levels of CORO1B, whereas it down-modulat-
ed RhoH in monocytes (P<0.05) (Figure 3C and D). These
modifications may account for the inhibition of monocyte
migration induced by lenalidomide. 
Lenalidomide induces activation and proliferation
of NLCs 
Peripheral blood-monocytes from CLL patients sponta-
neously differentiate in vitro into large adherent cells, the
so-called NLCs that deliver survival signals to leukemic
cells.18,28 We confirmed that lenalidomide reduced CLL sur-
vival in contact with NLCs from 54.2% to 44.5% after ten
days (n=5; P<0.05) (Online Supplementary Figure S1), as
reported by Schulz et al.17 
The next part of the study was dedicated to the analysis
of the effect of lenalidomide treatment on NLCs. First, we
cultured PBMCs from 9 CLL patients for ten days with 
0.5 mM or 1 mM lenalidomide or vehicle. The number of
NLCs was significantly increased upon treatment with
lenalidomide to 268% (±37%) and 309% (±73%) com-
pared to untreated control (100%) (n=9; P<0.01 and
P<0.05, respectively) (Figure 4A and B). We observed an
increase in NLC activation to 161% (±18%) as measured
by solubilization of intracellular purple formazan, after
treatment with lenalidomide for five days, compared to
untreated control (100%) (n=6; P<0.05) (Figure 4C).
Accordingly, lenalidomide stimulated NLC proliferation
after five days of culture from 44% (±3%) to 55% (±3%)
of dividing cells (n=5; P<0.01) (Figure 4D). NLC prolifera-
tion was also confirmed by Ki-67 staining and cell cycle
analysis (Online Supplementary Figure S2). Lenalidomide
increased the percentage of Ki-67+NLCs from
7.01%±2.09% to 9.42%±2.12% (n=6; P<0.01).  It has to
be considered that NLCs protect CLL from apoptosis in a
contact-dependent fashion. Surprisingly, we found that
CLL cells, despite a lower viability, were more adherent to
NLCs treated with lenalidomide 0.5 mM and 1 mM, with a
mean increase of 227% (±91%) and 212% (±54%),
respectively (n=6; P<0.05) (Figure 4E). 
Taken together, these findings indicate that lenalido-
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Figure 3. Lenalidomide reduces migration of
monocytes from CLL patients. (A) Monocytes
purified from 5 CLL patients were loaded in the
upper chamber of 5-mm pore PET inserts with
the addition of 0.5 mM lenalidomide or vehicle
(DMSO). CCL2 (10 ng/mL), CCL3 (10 ng/mL), or
CXCL12 (200 ng/mL) were added in the bottom
chamber as chemoattractants. Monocytes were
allowed to migrate for 4 h and migrated cells
were quantified by fluorescence plate reader.
Data are normalized on control (100%, DMSO-
treated monocytes). Histograms represent
mean±SEM of 5 independent experiments
(Student t-test, *P<0.05).  (B and C) Monocytes
purified from 6 CLL patients were cultured in 
24-well plates with 0.5 mM lenalidomide or vehi-
cle (DMSO) for 4 h. (B) Gene expression of CCR1,
CCR2, CXCR4, and (C) gene expression of RhoH
and CORO1B, were measured by quantitative
reverse-transcription PCR. Results of 2 inde-
pendent experiments with 6 patient samples
are presented as box plots; whiskers show min
and max values. Lenalidomide does not modify
CCR1, CCR2 and CXCR4 expression on CLL
monocytes. Conversely, CORO1B is significantly
up-regulated and RhoH down-regulated by
lenalidomide treatment (Student t-test,
*P<0.05). (D) Immunoblots show CORO1B and
RHOH quantities after treatment with lenalido-
mide 0.5 mM in a representative sample of CLL
monocytes. Densitometric quantification of
bands normalized to the untreated control is
shown below the immunoblots.
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mide supports the formation of NLCs from PBMCs of CLL
patients by promoting cell activation and proliferation.
However, NLCs generated in the presence of lenalidomide
adhere closely to CLL cells but fail to efficiently sustain
leukemic cell viability, prompting us to explore the func-
tional and molecular features of lenalidomide-treated
NLCs. 
Lenalidomide-treated NLCs improve the phagocytic
activity and activate T-cell proliferation 
Published evidence suggests that NLCs are closely relat-
ed to tumor-associated macrophages (TAM), showing M2-
skewed properties.3,5,7 We then asked ourselves whether
lenalidomide could interfere with the immunosuppressive
profile of NLCs. In agreement with observations in mono-
cytes, we found a strong stimulation of F-actin content in
lenalidomide-treated NLCs (Figure 5A). In line with our
hypothesis, NLCs (n=6) significantly increased their
phagocytic activity to 141% (±16%) and 155% (±9%),
respectively, after lenalidomide exposure (0.5 mM and
1mM for 4 h; n=6; P<0.05) (Figure 5B). Consistently, the
same treatment increased FITC-dextran uptake by NLCs
(n=8; P<0.01) (Figure 5C). Treatment with the Rap1
inhibitor before stimulation with lenalidomide was fol-
lowed by a strong impairment in phagocytosis (P<0.05)
(Figure 5D), suggesting that small GTPases may be a com-
mon target of lenalidomide. We then evaluated T-cell pro-
liferation in an allogeneic mixed lineage reaction. NLCs
(n=6), treated or not with lenalidomide 
0.5 mM overnight, were cultured for 7 days with CFSE-
labeled T lymphocytes from healthy donors (HD) in fresh
medium. T-cell proliferation increased both in the pres-
ence of NLCs (P<0.05) and with aCD3/CD2/CD28-coat-
ed beads (positive control) (P<0.01) compared to unstimu-
lated conditions. Moreover, lenalidomide-treated NLCs
strongly improved T-cell proliferation from 20% (±6%) to
35% (±11%) (n=6; P<0.05) (Figure 5E and F).
Lenalidomide modifies gene expression profile and
immunophenotype of NLCs
Gene expression profiles of NLCs (n=4), generated with
lenalidomide or vehicle-control (0.5 mM for 10 days), were
analyzed by microarrays (control sample vs. lenalidomide-
treated sample). Supervised analysis identified 584 genes
that were differentially expressed upon lenalidomide
treatment: 352 up-regulated and 232 down-regulated
(P<0.05). Classifying the modulated entities into biological
function categories by Gene Ontology, we found that
lenalidomide-induced signature was enriched in genes
involved in immune response, activation/proliferation of
T cells, complement activation, antigen processing and
presentation as well as regulation of cellular movement,
cytokine and chemokine activity (Figure 6A). In particular,
modulation of several chemokines such as CXCL11,
CXCL9, CCL19, XCL1 and XCL2 (up-regulated) or CCL2
and CXCL12 (down-regulated) was apparent (Figure 6B).
Furthermore, NLCs generated in the presence of lenalido-
mide, showed upregulation of IL12B (FC=1.9), IL2
(FC=1.8), and TNFSF4 (FC=2.8), and downregulation of
IL17D (FC=-2.4), ANGPT2 (FC=-2.3), IGF1 (FC=-5.4), and
Lenalidomide effect on NLCs
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Figure 4. Lenalidomide modifies the number
and functional properties of nurse-like cells.
NLCs were generated from PBMCs isolated
from CLL patients in presence or absence of
lenalidomide. (A) Number of NLCs were deter-
mined by CD14 staining and analyzed by flow
cytometry for each condition (n=9, Student 
t-test, *P<0.05, **P<0.01). (B) May-Grunwald
Giemsa staining documented the high number
of NLCs induced by treatment with lenalido-
mide 0.5 mM and 1 mM compared to untreated
control in a representative case. (C) Histograms
represent the formazan release by metabolical-
ly active NLCs treated with lenalidomide 
0.5 mM compared to untreated control. Data
are presented as mean±SEM of 6 independent
experiments performed in triplicates (Student t-
test, *P<0.05). (Bottom panels) Representative
phase-contrast micrographs demonstrating
increased NLCs activation (as insoluble for-
mazan purple precipitate) after treatment with
lenalidomide. (D) CFSE-labeled PBMCs collect-
ed from 5 CLL patients were cultured for five
days either in presence or absence of lenalido-
mide 0.5 mM. Box plot represents the prolifera-
tive rate of NLCs in each condition, stained with
CD14 antibody and analyzed by flow cytometry
(Student t-test, **P<0.01). (Bottom)
Histograms represent one representative case
of NLCs treated or not with lenalidomide.
Values indicate the percentage of proliferating
cells with low expression of CFSE. (E)
Histograms represent the mean relative adhe-
sion (±SEM) of CLL cells to NLCs in the pres-
ence or absence of lenalidomide compared to
control (n=6; Student t-test, *P<0.05). (Right)
May-Grunwald Giemsa stainings demonstrate
the increased adhesion of CLL cells to NLCs
after treatment with lenalidomide.
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HGF (FC=-2.1). Among the up-regulated genes in NLCs
generated with lenalidomide, we also detected IDO1
(FC=3.6) and the lysosomal-associated protein 3 (LAMP3,
FC=1.5), as well as SPON2, opsonin for macrophage
phagocytosis of bacteria (FC=8.8), genes coding for CD1
molecules that mediate the presentation of lipid and gly-
colipid antigens, and CD209 involved in pathogen-recog-
nition and endocytosis (FC=1.7). Moreover, lenalidomide
induced the downregulation of CD163 (FC=-2.0), EDNRB
(FC=-2.2) and TLR5 (FC=-1.6). The upregulation of IL2
and IDO1 in NLCs (n=8) generated with/without lenalido-
mide was confirmed by real-time PCR (Figure 6C).
Accordingly, lenalidomide increased the percentage of
NLCs secreting IL-2 protein (Figure 6D). The modulation
of gene expression of IL10 and IL8 (showing a borderline
significance in the microarray data) was also evaluated by
real-time PCR, and showed a downregulation of both
genes (71% for IL10, P<0.05; 60% for IL8, P<0.01) (Figure
6C). Lastly, we quantified the surface expression levels of
CD11b, the activated epitope MAC-1 and CD163 on
CD14+ NLCs. Lenalidomide-treated NLCs expressed sig-
nificantly higher levels of CD11b and MAC-1 (P<0.05 for
CD11b; P<0.05 for MAC-1) (Figure 6E) and lower levels of
CD163 (P<0.05) (Figure 6E).
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Figure 5. Lenalidomide enhances phagocytosis and the ability to stimulate T-cell proliferation in NLCs. (A) Actin polymerization was strongly
increased in NLCs after treatment with lenalidomide in one representative CLL patient. F-actin content was inspected by rhodamine-phalloidin
staining. (B) NLCs obtained from 6 CLL patients were treated or not with lenalidomide 0.5 mM and 1 mM for 4 h, followed by phagocytosis
assay. Data represent mean±SEM of 6 independent experiments (Student t-test, *P<0.05, **P<0.01). (C) Box plots summarize FITC-Dextran
uptake by NLCs treated or not with lenalidomide relative to 8 independent experiments; whiskers show min and max values (Student t-test,
**P<0.01). (Right) First row shows confocal staining of NLCs with FITC-dextran, phalloidin and DAPI; second row shows FITC-dextran, cave-
olin-1 and DAPI staining. (D) NLCs generated from 3 CLL patients were treated or not with Rap1 inhibitor (GGTI) for 30 min and then stimu-
lated with lenalidomide 1 mM for 4 h. Rap1 inhibitor affects lenalidomide-induced phagocytosis in NLCs. Histogram shows mean±SEM of 3
independent experiments (Student t-test, *P<0.05). (E and F) T cells from healthy donors were cultured on NLCs treated or not with lenalido-
mide 0.5 mM overnight. CD3+ cell proliferation was measured after 7 days by CFSE staining. (E) Box plot shows the improvement in T-cell pro-
liferation (as %CFSE-low CD3+ cells) on lenalidomide-treated NLCs (Student t-test, n=6, P<0.05). (F) Representative histograms show CFSE
proliferation profiles of healthy T cells cultured onto NLC layer pre-treated or not treated with lenalidomide overnight. T cells cultured alone
for seven days or stimulated with αCD3/CD2/CD28-coated beads are shown as negative and positive controls, respectively. 
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Discussion
In this study, we demonstrate that lenalidomide alters
the migratory and adhesive properties of
monocyte/macrophage populations in CLL. Moreover,
lenalidomide counteracts the ability of leukemic cells to
generate a macrophage population, defined as nurse-like
cells, characterized by an immunosuppressive, M2-
skewed and nursing profile. Instead, lenalidomide pro-
motes the expansion of a macrophage population with
M1 phenotype, characterized by enhanced phagocytic
activities and support to T-cell proliferation, with less abil-
ity to nurture leukemic cells. 
We found that lenalidomide strongly induces cytoskele-
ton reorganization through activation of small GTPases in
monocytes isolated from CLL patients. Consequently, this
induction of actin polymerization is reduced, even if not
completely neutralized, by using specific inhibitors for
Rap1, Rac1 and RhoA, suggesting that lenalidomide exerts
its mechanism of action by orchestrating the concomitant
activation of several GTPases. Actin cytoskeleton reorgan-
ization is essential during immune response, regulating
cell motility, migration, extravasation, antigen recognition
and phagocytosis.29 In particular, Rac1 mediates the forma-
tion of lamellipodia at the leading edge and activation of
integrin allowing a stable adhesion.30,31 Activation of Rap1
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Figure 6. Lenalidomide induces pro-inflammatory modification in NLCs. (A) Heat map shows differentially expressed genes between NLCs
treated and not treated with lenalidomide for ten days. (B) Histograms represent fold change of normalized intensity values of genes
expressed in NLCs treated with lenalidomide 0.5 mM to untreated control. (C) Histograms represent the mRNA relative quantity of IL2, IL10,
IDO1, IL8 evaluated by RT-PCR in NLCs obtained from 7 CLL patients (Student t-test, *P<0.05, **P<0.01). (D) Box plots show the percentage
of IL-2 secreting cells in NLCs populations treated or not with lenalidomide for 10 days relative to 4 independent experiments; whiskers shown
min and max values (Student t-test, *P<0.05). (E) Histograms show the fluorescence intensity of NLCs after treatment with lenalidomide
stained with anti-MAC1, anti-CD11b and anti-CD163 Abs in one representative sample. (Left). Values of untreated and treated samples (n=5)
are connected by lines (Student t-test, *P<0.05, **P<0.01).  
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induces a redistribution of integrin from uropod to the
leading edge necessary for immunological synapse forma-
tion, macrophage phagocytosis and migration.32,33 We
demonstrate that lenalidomide stabilizes firm adhesion of
monocytes to endothelium through stimulation of Rac1
and Rap1, also activating both PI3K and ILK. Stimulation
of PI3K, induced by Rap1, activates Rac1, cell adhesion
and pseudopod formation.34 In addition, ILK is a regulator
of adhesion, cell spreading, migration through integrin
activation modulating intracellular signaling pathways,
and recruiting molecules involved in actin
polymerization.29,35,36 Similarly, lenalidomide was reported
to target Rho GTPase signaling and to promote Rap1 traf-
ficking to the membrane, restoring the adhesion and
motility function of T cells from CLL patients.16
Nevertheless, we observed that lenalidomide reduces
the migratory capacity of monocytes derived from CLL
patients. Since lenalidomide does not affect the viability of
monocytes and the expression of chemokine receptors, its
inhibitory effect on migration is most likely related to
intracellular modification of cytoskeletal molecules. One
possible explanation may account for the simultaneous
activation of GTPases by lenalidomide. Constitutively
active Rac1 inhibits growth-factor-induced migration,
because lamellopodia extend all around the cells blocking
polarization. Similarly, constitutively activated RhoA
maintains cells unpolarized, thus abolishing the chemotac-
tic response,37 and Rap1 suppresses cell migration.38 Other
modifications of cytoskeletal molecules induced by
lenalidomide in CLL-monocytes are the upregulation of
the coronin CORO1B and the downregulation of RhoH
GTPase. Coronins are actin-binding proteins that regulate
lamellopodia protrusion, whole-cell motility and chemo-
taxis. CORO1B inhibits actin filament nucleation and its
downmodulation is required for smooth muscle cell
migration.39 Moreover, it is well known that RhoH is
strictly required for cell migration in response to CXCL12.
The diminished level of RhoH in monocytes treated with
lenalidomide could impair the cellular distribution of
phosphorylated focal adhesion kinase that fails to effec-
tively co-ordinate the activation of the Rho GTPases
RhoA and Rac, leading to defective migration.26 The capa-
bility of lenalidomide to restrain monocyte migration is in
line with studies demonstrating that this drug also inter-
feres with CLL cell chemotaxis, suggesting that CORO1B
upregulation and RhoH downregulation may be involved
in migration impairment induced by lenalidomide in CLL
cells and monocytes.17,26 Conversely, high levels of RhoH
in the presence of chemokine signals impair T-cell chemo-
taxis, explaining the opposite promoting effect of lenalido-
mide on T-cell migration. In treated CLL patients, lenalido-
mide would be expected to restrain monocyte migration
towards chemokine gradients generated by CLL-infiltrat-
ed cells.
In CLL, in vitro, a subset of CD14+ mononuclear cells
from CLL patients differentiates into large, round adherent
cells called NLCs.18 Lenalidomide treatment resulted in sig-
nificantly increased numbers of NLCs. We correlated this
increased development of NLCs to a strong stimulation in
their activation and proliferation status induced by
lenalidomide. It has to be considered that the percentage
of CD14+Ki67+ NLCs was approximately 7% after five
days of culture without lenalidomide. Conversely, we
detected less than 1% of CD14+Ki67+ cells in culture from
healthy donors (data not shown), in accordance with data
reported in literature;40 this means that the presence of
CLL cells is able to induce the proliferation of CD14+ cells.
Lenalidomide significantly improved the proliferation rate
of NLCs. Despite the high number of NLCs induced by
lenalidomide, NLCs maintain the ability to attract and to
establish physical contact with CLL cells, but lose the abil-
ity to nurture the CLL leukemic clone. Accordingly, we
demonstrated that lenalidomide induces the downregula-
tion of genes involved in pivotal pro-survival signals for
CLL, such as CCL2,41,42 CXCL1218 and IGF1.43
Previous studies demonstrated that NLCs are character-
ized by deregulation of genes involved in the process of
phagocytosis.8 Here, we examined the ability of lenalido-
mide to stimulate NLCs to engulf and ingest particles.
Lenalidomide improves the content of F-actin in NLCs and
their phagocytic activity. Interestingly, this effect was
abolished by blocking Rap1 GTPase, thus indicating that
Rap1 activation is essential for lenalidomide-mediated
NLCs-phagocytosis. Activation of Rap1 has been demon-
strated to be essential for phagocytosis by promoting the
polymerization of actin filament at the site membrane
beneath the forming phagosome and by functionally acti-
vating MAC-1 (CD11b/CD18), and bolstering the inte-
grin-dependent events necessary for effectuating the
phagocytic response.33,44 
It is well known that monocytes isolated from CLL
patients have immunosuppressive properties character-
ized by a strong reduction in T-cell proliferation, and this
anti-proliferative effect is caused, in part, by TGFβ, IDO1
and IL10.5,7,21 We observed that lenalidomide is able to
improve the ability of NLCs to stimulate T-cell prolifera-
tion. In line with these findings, a switch of NLCs proper-
ties to a pro-inflammatory profile was supported by gene
expression profiling analysis. Specifically, we found that
lenalidomide seems to modulate a peculiar cluster of genes
involved in the polarization of monocytes towards classi-
cal activated macrophages (M1) induced by LPS and IFN-
γ, i.e IDO1 and LAMP3.45 The role of IDO1 in the immune
response is still controversial, implying a possible involve-
ment in M1 polarization or alternatively in immune toler-
ance.7,46,47 Lenalidomide up-regulated IDO1 expression in
NLCs. One possible explanation may account for the
counter regulatory role of IDO1 to restrain excessive or
inappropriate immune activation during an inflammatory
response mediated by lenalidomide. Alternatively, a dose-
dependent mechanism of IDO1 function may be envi-
sioned.  We also observed a decreased expression of
CD163, a peculiar marker of NLCs, after treatment with
lenalidomide. CD163 expression is a marker of M2
macrophages; its function is carried out through scaveng-
ing of the haptoglobin-hemoglobin complex and produc-
tion of anti-inflammatory metabolites.48 Upregulation of
IL2 and downregulation of IL10 in lenalidomide-treated
NLCs may be expected to be involved in the recovery of
T-cell proliferation. IL2 is a potent inducer of T-cell prolif-
eration and IL10 is an M2 cytokine, strongly expressed in
NLCs, that is involved in immunosuppression. Finally,
lenalidomide reduces the expression of IL8 that not only
promotes cell invasion and increases macrophage infiltra-
tion, but also protects CLL cells from apoptosis.49 
CLL patients are typically immunocompromised with
defective function of T lymphocytes, NK cells and acces-
sory cells, and this could promote a tollerogenic milieu for
leukemic cells. On the other hand, there is some evidence
to show that an inflammatory microenvironment is
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induced in survival-supporting culture of CLL cells and
that the levels of some inflammatory cytokines are
increased in sera of CLL patients compared to healthy con-
trols.42,50 However, CLL patients with good outcome are
characterized by higher levels of several pro-inflammatory
cytokines (IL-2, IL-4, IL-15, IL-1β, IL-6, TNFa) as com-
pared to CLL with poor outcome. This implies that a more
aggressive disease is accompanied by a progressive sup-
pression of immune cell activation and anti-tumor
responses. 
Our data provide new insights into the mechanism of
action of lenalidomide that induces an ‘immune re-educa-
tion’ of NLCs. Lenalidomide interferes with the support-
ing and protective microenvironment generated by CLL
cells inside tissue niches and counteracts the pro-leukemia
role and the immunodeficiency typical of NLCs inducing
properties of pro-inflammatory cells.
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